Instruction for use: Levodopa

The Latin name of the substance Levodopa

Levodopum (genus. Levodopi)

Chemical name

3-Hydroxy-L-tyrosine

Gross Formula

C₉H₁₁NO₄

Pharmacological groups:

Dopaminomimetics

Anti-Parkinsonics

The nosological classification (ICD-10)

G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism

G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome

CAS Code

59-92-7

Characteristics of substance Levodopa

White crystalline powder. Slightly soluble in water, insoluble in alcohol.

Pharmacology

The pharmacological action is antiparkinsonian.

It is a precursor of dopamine. It penetrates through the BBB, accumulates in the basal ganglia and turns into dopamine, replacing the lack of the latter in the extrapyramidal system. As a consequence, muscle stiffness and hypokinesia decrease. Well absorbed when taken orally; Cmax is determined after 1-2 hours, some part of it already in the blood is transformed into dopamine and does not enter the basal nuclei (dopamine does not pass the BBB). It is excreted mainly by the kidneys.

Application of substance Levodopa

Parkinson's disease, symptomatic parkinsonism.

Contraindications

Hypersensitivity, severe atherosclerosis, hypertension, liver, kidney, blood, glaucoma, melanoma, bronchial asthma, mental illness, uncompensated pathology of cardiovascular, respiratory, endocrine systems.

Restrictions on the use

Pregnancy, breastfeeding, children's age (up to 12 years), myocardial infarction in the anamnesis.

Side effects of Levodopa

Choreoathetoid hyperkinesis, arrhythmia, psychotic and paranoid reactions, dyspeptic phenomena, gastrointestinal ulceration, headache, dizziness, visual impairment, hemolytic anemia, agranulocytosis and leukopenia, alopecia, allergic reactions.

Interaction

The effect weakens vitamin B6. Enhances the effect of MAO inhibitors.

Routes of administration

Inside.